Investing.com -- Immunome (NASDAQ:IMNM) stock surged 30% after the biotechnology company announced positive topline results from its Phase 3 RINGSIDE trial of varegacestat in patients with desmoid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback